科研之友ScholarMate
免费注册
首页 论文 论文详情
赞 收藏 引用

Are the cardiovascular risk reductions seen with empagliflozin in the EMPA-REG OUTCOME trial explained by conventional cardiovascular risk factors?

作者：Coleman R L; Gray A; Broedl U C; Fitchett D; George J T; Woerle H J; Zinman B; Holman R R
来源：53rd Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD), 2017-09-11 To 2017-09-15.
DOI：10.1111/dme.33_13304
  • 出版日期2017-3

全文

全文

访问全文
收藏 分享 被引 浏览
更新时间：2021-01-19 06:12